Calcineurin inhibitors revisited: A new paradigm for COVID-19?
Braz. j. infect. dis
;
24(4): 365-367, Jul.-Aug. 2020. tab
Article
in English
| LILACS, ColecionaSUS
| ID: biblio-1132459
ABSTRACT
Abstract The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can cause mild, moderate or severe disease (COVID-19). In severe disease, there is hyperinflammation causing severe symptoms. Severe COVID-19 is an immunological phenomenon, rather than a direct viral damage disease. Therapies for COVID-19 are all investigational therapies. In case of severe disease, treatment with a calcineurin inhibitor could be promising. In this article we explain the mechanisms of calcineurin inhibitor treatment for COVID-19, based on experiences seen in solid organ transplant recipients who suffered from COVID-19.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Calcineurin Inhibitors
Limits:
Humans
Language:
English
Journal:
Braz. j. infect. dis
Year:
2020
Type:
Article
Institution/Affiliation country:
University Hospital Zurich/CH
Similar
MEDLINE
...
LILACS
LIS